WO2003072045A3 - Treatment and prevention of aids progression and methods of using same - Google Patents

Treatment and prevention of aids progression and methods of using same Download PDF

Info

Publication number
WO2003072045A3
WO2003072045A3 PCT/US2003/005514 US0305514W WO03072045A3 WO 2003072045 A3 WO2003072045 A3 WO 2003072045A3 US 0305514 W US0305514 W US 0305514W WO 03072045 A3 WO03072045 A3 WO 03072045A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutation
sequence encoding
hiv
treatment
prevention
Prior art date
Application number
PCT/US2003/005514
Other languages
French (fr)
Other versions
WO2003072045A2 (en
Inventor
Ghalib Alkhatib
Original Assignee
Indiana University
Ghalib Alkhatib
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University, Ghalib Alkhatib filed Critical Indiana University
Priority to AU2003213256A priority Critical patent/AU2003213256A1/en
Publication of WO2003072045A2 publication Critical patent/WO2003072045A2/en
Publication of WO2003072045A3 publication Critical patent/WO2003072045A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

There is provided a method of protecting individuals from contracting HIV by administering either a vector or a vaccine containing a sequence encoding the Δ32 mutation. Also provided is a method of decreasing the amount of HIV co-receptors present on the cell surface by administering a compound including a sequence encoding the Δ32 mutation in a pharmaceutically acceptable carrier. Also provided is a compound for decreasing the amount of HIV co-receptors present in the cell surface, the compound having a sequence encoding the Δ32 mutation in a pharmaceutically acceptable carrier. Also provided is a vector containing a sequence encoding the Δ32 mutation. An assay for testing the efficacy of HIV treatment is also provided, the assay includes a detector for detecting the presence of the Δ32 mutation in cells.
PCT/US2003/005514 2002-02-22 2003-02-20 Treatment and prevention of aids progression and methods of using same WO2003072045A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213256A AU2003213256A1 (en) 2002-02-22 2003-02-20 Treatment and prevention of aids progression and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35891202P 2002-02-22 2002-02-22
US60/358,912 2002-02-22

Publications (2)

Publication Number Publication Date
WO2003072045A2 WO2003072045A2 (en) 2003-09-04
WO2003072045A3 true WO2003072045A3 (en) 2003-11-27

Family

ID=27766018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005514 WO2003072045A2 (en) 2002-02-22 2003-02-20 Treatment and prevention of aids progression and methods of using same

Country Status (2)

Country Link
AU (1) AU2003213256A1 (en)
WO (1) WO2003072045A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108300700A (en) * 2018-02-05 2018-07-20 翁炳焕 A kind of preparation of gene sequencing calibration Reference Strains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCKENZIE ET AL.: "Nucleic acid vaccines", IMMUNOLOGIE RESEARCH, vol. 24, no. 3, 2001, pages 225 - 244, XP002968550 *

Also Published As

Publication number Publication date
AU2003213256A8 (en) 2003-09-09
WO2003072045A2 (en) 2003-09-04
AU2003213256A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2005025292A3 (en) System and method for risk based authentication
TW358978B (en) Method to etch a destruction-area on a semiconductor substrate-edge as well as an etching equipment
WO2004007679A3 (en) Dendritic cell pontentiation
AU2003253765A1 (en) System and method for locating and notifying a user of a person, place or thing having attributes matching the user's stated prefernces
IL125662A0 (en) Method of detecting influenza virus and compounds for use therein
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
EP1026263A3 (en) Oligonucleotide reverse transcription primers for efficient detection of HIV-1 and HIV-2 and methods of use thereof
HUP0102990A2 (en) Tetrahydroimidazo-naphtyridine derivatives and pharmaceutical compositions thereof
WO2004014926A8 (en) Alkoxyamines originating from beta-phosphorylated nitroxides and use thereof in radical polymerisation
AU2002360853A1 (en) System and method of detecting, neutralizing, and containing suspected contaminated articles
TW327700B (en) The method for using rough oxide mask to form isolating field oxide
EP1449835A3 (en) Alpha-substituted pyrimidine-thioalkyl and alkylether compounds
MY138243A (en) Process for the back-surface grinding of wafers.
WO2001059457A3 (en) Assay for detection of viral fusion inhibitors
WO2001098460A3 (en) Fusion proteins of mycobacterium tuberculosis
WO1995001168A3 (en) Pharmaceutical preparations that contain an active substance with modified amidine groups
WO2001011006A3 (en) Detection of micro-organisms
WO2002054072A3 (en) Assay to determine efficacy of treatment for mycobacterial infection
WO2003015708A8 (en) Composition and method for treating hiv infection
WO2003045327A3 (en) Efavirenz tablet formulation having unique biopharmaceutical characteristics
WO2003072045A3 (en) Treatment and prevention of aids progression and methods of using same
WO2004016283A3 (en) Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
AU1599601A (en) Human igm antibodies to chemokine receptors
WO2003081253A3 (en) Electrochemical multi-well plate
WO2002094884A3 (en) Methods and compositions for inhibiting polymerization of vinyl monomers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP